pharma · Duchenne Muscular Dystrophy · Duchenne Muscular Dystrophy (DMD) · TRDA
Entrada Therapeutics
Entrada Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2016
- Employees
- 201
- Programs
- 4
- Drugs
- 4
- Patents
- 5
Entrada Therapeutics projects
4 ClinicalTrials.gov programs sponsored by Entrada Therapeutics.
Entrada Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ENTR-601-44
Entrada Therapeutics
Duchenne Muscular Dystrophy (DMD)
1 trial -
ENTR-601-44, SODIUM CHLORIDE
Entrada Therapeutics
Duchenne Muscular Dystrophy
1 trial -
ENTR-601-45
Entrada Therapeutics
Duchenne Muscular Dystrophy (DMD)
1 trial -
SODIUM CHLORIDE, ENTR-601-45
Entrada Therapeutics
Duchenne Muscular Dystrophy
1 trial
Frequently asked questions
How many clinical projects does Entrada Therapeutics have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.